8-K: Whitehawk Therapeutics Launches with Focus on ADC Therapies, Expects Cash Runway into 2028

Aadi Bioscience rebrands as Whitehawk Therapeutics, shifting focus to antibody drug conjugates (ADCs) and anticipating operational funding into 2028 following strategic transactions.

Summary

• Aadi Bioscience has rebranded as Whitehawk Therapeutics, signaling a strategic shift towards developing antibody drug conjugates (ADCs).
• The company's stock will trade on Nasdaq under the ticker WHWK starting March 19, 2025.
• Whitehawk Therapeutics is focusing on a portfolio of three ADC assets in-licensed from WuXi Biologics, utilizing HANGZHOU DAC's advanced ADC technology platform.
• The company anticipates that its cash reserves will fund operations into 2028, enabling key clinical data readouts for its ADC assets.
• The company reported $7.2 million in revenue for the fourth quarter of 2024 and $26.0 million for the full year, stemming from sales of FYARRO.
• Net loss for the fourth quarter of 2024 was $18.3 million, and $63.7 million for the full year.
• As of December 31, 2024, cash, cash equivalents, and short-term investments totaled $47.2 million.
• Following the closing of strategic transactions, the company expects to have cash and cash equivalents in the range of $170 million to $180 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strategic shift towards ADC therapies, expected cash runway into 2028, and the closing of the PIPE financing. However, the net losses and decrease in cash reserves temper the overall sentiment.

Positives

• The company's strategic shift towards ADC therapies could lead to improved cancer treatments.
• The company expects to have cash and cash equivalents in the range of $170 million to $180 million following the closing of strategic transactions.
• The company anticipates that its cash reserves will fund operations into 2028, enabling key clinical data readouts for its ADC assets.
• The company has a portfolio of three ADC assets in-licensed from WuXi Biologics.
• All proposals were approved at the Company's Special Meeting of Stockholders on February 28, 2025, and the $100 million PIPE financing closed.

Negatives

• The company reported a net loss of $18.3 million for the fourth quarter of 2024 and $63.7 million for the full year.
• Cash, cash equivalents and short-term investments decreased from $108.8 million as of December 31, 2023 to $47.2 million as of December 31, 2024.

Risks

• The company faces uncertainties associated with preclinical and clinical development of its ADC portfolio, including potential delays in trials.
• There is a risk that the ADC portfolio may not demonstrate efficacy in preclinical and clinical studies.
• Unforeseen adverse reactions or side effects may occur during the testing of the ADC assets.
• One or more closing conditions to the pending sale of Aadi Sub to Kaken may not be satisfied.
• The company's estimates regarding future expenses, capital requirements, and the need for additional financing may be inaccurate.

Future Outlook

Whitehawk Therapeutics anticipates its cash reserves will fund operations into 2028, enabling key clinical data readouts for its ADC assets, and plans to bring all three ADC assets to IND in the next 15 months.

Management Comments

• David Lennon, President and CEO, stated that the company is combining science, strategy, and execution to swiftly advance its portfolio of promising ADC assets.
• David Lennon, President and CEO, mentioned the goal is to bring all three assets to IND in the next 15 months.
• David Lennon, President and CEO, believes the robust balance sheet will enable the company to see these three assets through early clinical inflections.

Industry Context

The shift towards ADC therapies reflects a broader trend in oncology towards targeted treatments with improved efficacy and reduced toxicity compared to traditional chemotherapy. The in-licensing of assets from WuXi Biologics indicates a strategic partnership to leverage advanced ADC technology.

Comparison to Industry Standards

• The company's focus on ADCs aligns with the industry's increasing interest in targeted cancer therapies, with companies like Seagen, ImmunoGen, and Daiichi Sankyo leading the way.
• The use of WuXi Biologics' HANGZHOU DAC platform is comparable to other companies utilizing specialized linker-payload technologies to enhance ADC efficacy and safety.
• The goal of achieving IND status for three assets within 15 months is an ambitious timeline, reflecting a commitment to rapid development, but is achievable based on industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders may experience changes in the company's stock value due to the strategic shift and name change.
• Employees will be affected by the company's new focus on ADC therapies and the divestiture of Aadi Sub.
• Patients with difficult-to-treat cancers may benefit from the development of improved ADC treatments.
• The company's suppliers and partners may be impacted by the shift in focus and the divestiture of Aadi Sub.

Next Steps

• The company plans to advance its three ADC assets to IND in the next 15 months.
• The company will conduct Phase 1 trials for HWK-007 in non-small cell lung cancer and platinum-resistant ovarian cancer.
• The company will conduct Phase 1 trials for HWK-016 in ovarian cancer.
• The company will conduct Phase 1 trials for HWK-206 in small-cell lung cancer and neuroendocrine neoplasms.
• The closing of the divestiture of Aadi Sub to Kaken Pharmaceuticals is pending.

Key Dates